Constipation is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Constipation have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Constipation compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Constipation overview
Constipation refers to infrequent bowel movements or difficulty passing stool, often accompanied by straining or discomfort. It arises from various factors, including inadequate fiber intake, dehydration, sedentary lifestyle, medications, or underlying medical conditions like irritable bowel syndrome or hypothyroidism. Symptoms may include bloating, abdominal pain, and a sensation of incomplete evacuation. Treatment involves lifestyle modifications such as increasing fiber intake, staying hydrated, and regular exercise. Over-the-counter laxatives or stool softeners may provide relief for short-term constipation, while addressing underlying causes is essential for long-term management. Persistent or severe cases warrant medical evaluation to rule out serious conditions and implement appropriate interventions.
For a complete picture of PTSR and LoA scores for drugs in Constipation, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
